Bremont F, Pienkowski C, Moisan V, Dutau G
Unité des Maladies Respiratoires et Allergiques de l'Enfant et de l'Adolescent, CHU Rangueil, Toulouse.
Ann Pediatr (Paris). 1990 Jun;37(6):360-4.
Five infants aged 7 to 17 months were treated for asthma with a continuous subcutaneous infusion of a beta 2-agonist for 6 to 11 days in a dosage of 0.1 microgram/kg/mn. The patients had a severe attack of asthma with problems with infusions and/or problems with nebulizations of beta 2-agonists and/or bronchial stasis. No local or systemic adverse effects were recorded. This mode of administration of beta 2-agonists proved extremely useful, either as single therapy or as part of a therapeutic protocol including antibiotics, steroids and theophylline. It avoids the problems met with administration of beta 2-agonists by the other routes and allows the child freedom of movement. The main indication is the severe attack of asthma that fails to respond to nebulizations. We suggest this new therapeutic method should be included in the therapeutic armamentarium for infantile asthma, although its exact place and indications need to be further defined by studies in a larger number of patients.
对5名年龄在7至17个月的婴儿进行哮喘治疗，采用皮下持续输注β2受体激动剂，剂量为0.1微克/千克/分钟，持续6至11天。这些患者患有严重哮喘发作，存在β2受体激动剂输注问题和/或雾化问题和/或支气管淤滞问题。未记录到局部或全身不良反应。事实证明，这种β2受体激动剂给药方式极为有用，既可以作为单一疗法，也可以作为包括抗生素、类固醇和茶碱在内的治疗方案的一部分。它避免了通过其他途径使用β2受体激动剂时遇到的问题，并使儿童能够自由活动。主要适应症是对雾化治疗无反应的严重哮喘发作。我们建议，这种新的治疗方法应纳入婴儿哮喘的治疗手段中，尽管其确切地位和适应症需要通过对更多患者的研究进一步明确。
